Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

• Biological: PF-04236921
  
  subcutaneous injection; administered at day 1, weeks 8, 16.
• Biological: PF-04236921
  
  subcutaneous injection; administered at day 1, weeks 8, 16

• 10 mg of PF-04236921
  
  Intervention: Biological: PF-04236921
• 50 mg of PF-04236921
  
  Intervention: Biological: PF-04236921
• 200 mg of PF-04236921
  
  Intervention: Biological: PF-04236921
• Placebo
  
  Intervention: Biological: PF-04236921

Inclusion Criteria:

• Male or female subjects between ages of 18 and 75 years old at time of signing consent.
• Have a clinical diagnosis of SLE according to 1997 update on the revised 1982 American College of Rheumatology (ACR) criteria.
• Have a unequivocally positive anti-nuclear antibody (ANA) test result.
• Active disease at screening defined by both: SLEDAI-2K score greater than or equal to 6 and BILAG Level A disease in more than or equal to 1 organ system (except renal or central nervous system) or BILAG B disease in more than or equal to 2 organ systems if no level A disease in present.

Exclusion Criteria:

• Any prior history of treatment with PF-04236921, or anti-IL-6 agent;
• Have received any of the following within 364 days of day 1: a biologic investigational agent other than B cell targeted therapy; required 3 or more courses of systemic corticosteroids for concomitant conditions; history of previously untreated or current evidence of active or untreated latent infection with Tuberculosis (TB), evidence of prior untreated or currently active TB by chest radiography, residing with or frequent close contact with an individual with active TB.